JP4733833B2 - アデノウィルスを介する遺伝子治療 - Google Patents

アデノウィルスを介する遺伝子治療 Download PDF

Info

Publication number
JP4733833B2
JP4733833B2 JP2000581225A JP2000581225A JP4733833B2 JP 4733833 B2 JP4733833 B2 JP 4733833B2 JP 2000581225 A JP2000581225 A JP 2000581225A JP 2000581225 A JP2000581225 A JP 2000581225A JP 4733833 B2 JP4733833 B2 JP 4733833B2
Authority
JP
Japan
Prior art keywords
tumor
adenovirus
patients
gene
cavity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000581225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002529097A5 (https=
JP2002529097A (ja
Inventor
セッポ・ユラ−ヘルッチュアラ
アヌ−マーリア・サンドマイル
サミ・ロイマス
マッティ・ヴァパラハティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ark Therapeutics Ltd
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4733833(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Publication of JP2002529097A publication Critical patent/JP2002529097A/ja
Publication of JP2002529097A5 publication Critical patent/JP2002529097A5/ja
Application granted granted Critical
Publication of JP4733833B2 publication Critical patent/JP4733833B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2000581225A 1998-11-06 1999-11-05 アデノウィルスを介する遺伝子治療 Expired - Fee Related JP4733833B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9824437.9 1998-11-06
GBGB9824437.9A GB9824437D0 (en) 1998-11-06 1998-11-06 Gene therapy
PCT/EP1999/009017 WO2000028059A1 (en) 1998-11-06 1999-11-05 Adenovirus-mediated gene therapy

Publications (3)

Publication Number Publication Date
JP2002529097A JP2002529097A (ja) 2002-09-10
JP2002529097A5 JP2002529097A5 (https=) 2006-12-21
JP4733833B2 true JP4733833B2 (ja) 2011-07-27

Family

ID=10842035

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000581225A Expired - Fee Related JP4733833B2 (ja) 1998-11-06 1999-11-05 アデノウィルスを介する遺伝子治療

Country Status (18)

Country Link
US (1) US6579855B1 (https=)
EP (1) EP1135513B2 (https=)
JP (1) JP4733833B2 (https=)
KR (1) KR20020013473A (https=)
CN (1) CN1184321C (https=)
AT (1) ATE341639T1 (https=)
AU (1) AU749451B2 (https=)
CA (1) CA2348624C (https=)
CY (1) CY1106198T1 (https=)
DE (1) DE69933468T3 (https=)
DK (1) DK1135513T4 (https=)
ES (1) ES2273521T5 (https=)
GB (1) GB9824437D0 (https=)
HU (1) HUP0104046A3 (https=)
NO (1) NO330776B1 (https=)
PL (1) PL193076B1 (https=)
PT (1) PT1135513E (https=)
WO (1) WO2000028059A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910950D0 (en) 2009-06-24 2009-08-05 Ark Therapeutics Ltd Filtration
GB0916997D0 (en) 2009-09-28 2009-11-11 Ark Therapeutics Ltd Combination therapy
US20130296407A1 (en) * 2011-01-18 2013-11-07 Ark Therapeutics, Ltd. Combination Therapy for Cancer
GB201100804D0 (en) * 2011-01-18 2011-03-02 Ark Therapeutics Ltd Drug combination
CA2863964C (en) 2012-02-07 2021-10-26 Global Bio Therapeutics Usa, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US20160058888A1 (en) * 2013-05-08 2016-03-03 Gliotherapy Limited Treatment of Operable High-Grade Glioma With Sitimagene Ceradenovec Gene Therapy and Ganciclovir
WO2015021443A1 (en) 2013-08-08 2015-02-12 Global Bio Therapeutics Usa, Inc. Clamp device for minimally invasive procedures and uses thereof
DE102019000490A1 (de) 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Verwendung von Oligonukleotiden für die Behandlung von Tumoren
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
MX2022014239A (es) 2020-05-12 2023-02-09 Regeneron Pharma Nuevos agonistas de il10 y metodos para su uso.
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
TW202321282A (zh) 2021-07-19 2023-06-01 美商再生元醫藥公司 Il12受體促效劑及其使用方法
TW202334223A (zh) 2021-11-11 2023-09-01 美商再生元醫藥公司 Ｃｄ２０－ｐｄ１結合分子及其使用方法
EP4649088A1 (en) 2023-01-13 2025-11-19 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
EP4649092A1 (en) 2023-01-13 2025-11-19 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
IL322890A (en) 2023-02-28 2025-10-01 Regeneron Pharma Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
EP4709756A1 (en) 2023-05-10 2026-03-18 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
WO2025106469A1 (en) 2023-11-14 2025-05-22 Regeneron Pharmaceuticals, Inc. Engineered heavy chain variable domains and uses thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0662441B2 (ja) * 1986-02-18 1994-08-17 花王株式会社 抗腫瘍物質徐放性製剤
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk

Also Published As

Publication number Publication date
ES2273521T3 (es) 2007-05-01
GB9824437D0 (en) 1999-01-06
KR20020013473A (ko) 2002-02-20
DK1135513T4 (da) 2011-11-21
CA2348624A1 (en) 2000-05-18
EP1135513A1 (en) 2001-09-26
WO2000028059A1 (en) 2000-05-18
US6579855B1 (en) 2003-06-17
DE69933468T3 (de) 2012-01-19
CN1325450A (zh) 2001-12-05
ATE341639T1 (de) 2006-10-15
ES2273521T5 (es) 2011-12-28
DE69933468D1 (de) 2006-11-16
HUP0104046A3 (en) 2003-09-29
CN1184321C (zh) 2005-01-12
CY1106198T1 (el) 2011-06-08
DE69933468T2 (de) 2007-01-11
NO20012220L (no) 2001-05-04
PT1135513E (pt) 2006-12-29
NO20012220D0 (no) 2001-05-04
NO330776B1 (no) 2011-07-11
PL193076B1 (pl) 2007-01-31
HUP0104046A2 (hu) 2002-01-28
CA2348624C (en) 2012-07-31
EP1135513B1 (en) 2006-10-04
DK1135513T3 (da) 2006-11-27
JP2002529097A (ja) 2002-09-10
AU749451B2 (en) 2002-06-27
EP1135513B2 (en) 2011-08-10
AU1385100A (en) 2000-05-29
PL349489A1 (en) 2002-07-29

Similar Documents

Publication Publication Date Title
JP4733833B2 (ja) アデノウィルスを介する遺伝子治療
JP4213201B2 (ja) 固型腫瘍、乳頭腫および疣贅の遺伝子治療
US7182944B2 (en) Methods of increasing distribution of nucleic acids
US6503888B1 (en) AAV-mediated delivery of DNA to cells of the nervous system
US10610606B2 (en) Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
Goodman et al. Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecular studies
JP2002516295A (ja) Ａａｖベクターの対流増加送達
JP2018509164A (ja) 組換えＧｌｕｔ１アデノ随伴ウイルスベクターコンストラクトおよびＧｌｕｔ１発現を回復させる方法
US20010012835A1 (en) Method of enhancing the effectiveness of dck phosphorylated molecules
JP2003518077A (ja) 血管形成および血管透過性の調節剤および阻害剤
WO2022255906A1 (en) Drug for genetic and gene-cell-based therapy
Shimizu et al. Infectious retrovirus is inactivated by serum but not by cerebrospinal fluid or fluid from tumor bed in patients with malignant glioma
MXPA01004410A (es) Terapia de gen mediada por adenovirus
CA2332634A1 (en) Repression of cell transformation with human pea3
US12246074B2 (en) Granulocyte colony-stimulating factor (GCSF) gene therapy for treating neurological diseases
Gøtzsche et al. Lalitha R. Belur1*, Megan Romero1, Junggu Lee1, Kelly M. Podetz-Pedersen1, Zhenhong Nan2, Maureen S. Riedl3, Lucy Vulchanova3, Kelley F. Kitto4, Carolyn A. Fairbanks4, Karen F. Kozarsky5†, Paul J. Orchard6, William H. Frey II7, Walter C. Low2 and R. Scott McIvor1
WO2024100176A1 (en) Controlled gene therapy of ocular diseases
WO2021158982A2 (en) Targeted translation of rna with crispr-cas13 to enhance protein synthesis
KR20220114028A (ko) 파킨슨병을 치료하는 방법
Brown et al. Retroviruses and DNA: gene therapy for brain tumours
Jimenez Gene therapy for malignant brain tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091117

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100105

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100217

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100317

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110218

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110310

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110405

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110425

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140428

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees